FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Tag: Pfizer Abrysvo RSV vaccine
All
Latest
FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Read More
RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults
Johns Hopkins Medicine says further research is needed to better understand the problem and find ways to enhance immune response in this high-risk population.
Read More
Best Window for RSV Vaccination During Pregnancy Identified
Current guidelines recommend RSV vaccination between 32-36 weeks of pregnancy, but researchers have identified the optimal time within that window for maximum newborn protection.
Read MorePfizer’s RSV Vaccine Approved for Adults Down to Age 18
The FDA has approved Pfizer’s RSV vaccine, Abrysvo, for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV, expanding its previous indication for adults aged 60 and older.
Read More
RSV Is Linked to Asthma in Children – But We Can’t Say One Causes the Other Yet
While respiratory syncytial virus, or RSV, is strongly associated with asthma in children, the exact relationship remains unclear.
Read MorePfizer’s RSV Vaccine Shows Promise in Immunocompromised Adults
Pfizer’s Abrysvo demonstrated a strong immune response and favorable safety profile in immunocompromised adults at high risk of severe RSV.
Read More
Under 75? CDC Revises RSV Vaccine Recommendations for High-Risk Only
The CDC’s updated guidance recommends vaccination only for high-risk adults aged 60-74, while strengthening its advice for adults 75 and older.
Read More
CDC: Nirsevimab 90% Effective Against RSV in Infants
CDC data show that nirsevimab was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus.
Read More
What Percentage of Older Adults Got RSV Vaccines? Hint: It’s Single Digits
A Texas A&M University School of Public Health study surveyed 1,345 Americans aged 60 and above on their RSV vaccination status.
Read More
Pfizer’s RSV Vaccine Protective Through Two Seasons in Older Adults
New top-line results show the bivalent vaccine maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose.
Read More
RSV Vaccine Added to ACIP 2024 Adult Immunization Schedule
The Advisory Committee on Immunization Practices has released its 2024 Recommended Adult Immunization Schedule which includes four new vaccines.
Read More
RSV Can Infect Nerve Cells and Enter Spinal Cord
Long thought to only infect the respiratory tract, a new study has found that RSV can infect nerve cells, cause nerve damage, and enter the spinal cord, potentially granting access to the central nervous system.
Read More
Canada Approves Pfizer’s RSV Vaccine
The vaccine was approved for older adults and infants through maternal immunization.
Read More
Full RSV Vaccination Could Cut Senior Hospitalizations by 91.7%
Respiratory syncytial virus vaccines recently approved for people 60 and older would dramatically reduce the disease’s burden of illness and death if they were widely adopted like annual influenza vaccines, a Yale University study finds.
Read More
CDC Endorses Pfizer’s Maternal RSV Vaccine to Shield Newborns
Members of the Advisory Committee on Immunization Practices voted 11-1 to recommend the maternal RSV vaccine for pregnant people to prevent RSV lower respiratory tract infection in infants.
Read More
FDA Approves First RSV Vaccine for Use During Pregnancy
The US FDA expanded Pfizer’s Abrysvo (RSV vaccine) for use during pregnancy to prevent LRTD caused by RSV in infants from birth through 6 months of age.
Read More
FDA Approves Pfizer’s RSV Vaccine
The FDA approved Abrysvo for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years and older.
Read More